Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, February 24, 2020
Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations.
read more
Samsung Biologics announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.
read more
Tuesday, November 28, 2023
Samsung Biologics, a prominent global contract development and manufacturing organization (CDMO), hosted its inaugural Suppliers ESG Day at its Songdo headquarters and online, marking a significant step toward sharing environmental, social, and ...
read more
Monday, December 14, 2020
Samsung Biologics officially began construction of its Plant 4 in Incheon, South Korea.
read more
Thursday, October 23, 2025
Samsung Biologics announced a shareholder-approved split of its business divisions, positioning itself as a pure-play contract development and manufacturing organization (CDMO). The move, passed with 99.9% approval at an extraordinary shareholders’ ...
read more
Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline.
read more
Samsung Biologics and TG Therapeutics have announced an expansion of a large-scale contract manufacturing deal for the supply of TG Therapeutics' ublituximab, an investigational anti-CD20 monoclonal antibody.
read more
Samsung Biologics, the world’s leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins. Under the ...
read more
Monday, February 11, 2019
Samsung Bioepis announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
read more
Thursday, December 03, 2020
Samsung Bioepis and Biogen announced the FDA has accepted for review the BLA for SB11, a proposed biosimilar referencing Lucentis.
read more
Friday, November 06, 2020
Samsung Bioepis has won a prestigious Biosimilar Initiative of the Year at the ‘Global Generics & Biosimilars Awards 2020’ held on November 03, 2020.
read more
Samsung Bioepis announced the U.S. Food and Drug Administration (FDA) has approved Renflexis, a biosimilar referencing Remicade, across all eligible indications.
read more
Monday, November 16, 2020
Samsung Bioepis announced the initiation of Phase 1 clinical trial for SB16, the company's proposed biosimilar referencing Prolia (denosumab).
read more
Wednesday, November 06, 2019
Samsung Bioepis has entered into a new commercialization agreement with Biogen for two biosimilar candidates under development by Samsung Bioepis, SB11 (ranibizumab) and SB15 (aflibercept).
read more
Wednesday, September 11, 2019
Samsung Bioepis announced its expansion into the Brazilian biopharmaceutical market.
read more